Meridian Bioscience, Inc. (VIVO) Enters Strategic Collaboration With Viral Therapeutics, Inc. 
10/19/2005 5:11:36 PM

Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a strategic collaboration with Viral Therapeutics, Inc. (VTI), Ithaca, NY, to support the clinical and commercial development needs of biopharmaceutical partners. Viral Therapeutics is an expert in the development of recombinant proteins and in production optimization. Viral Antigens' expertise is in the areas of process development and clinical stage manufacturing of biopharmaceuticals. The companies are coordinating their marketing efforts to provide a wider range of biopharmaceutical enabling technologies to better service their clients in the development and production of recombinant proteins, therapeutic antibodies, and vaccines.